RISK ASSESSMENT OF CARDIOVASCULAR DISEASE IN PREGNANCY
Keywords:
eclampsia, placental, hypoxia, pathology, cardiovascularAbstract
In recent years, the incidence of cardiovascular disease (CVD) in young pregnant women is increasing. This is thought to be due to increased age at birth, cardiovascular risk factors (obesity, diabetes, hypertension), and lifestyle changes in patients. It can be a congenital heart disease caused by various congenital and acquired rheumatism. Cardiovascular disease remains the leading cause of death in women.
References
D. Muraru and E. Surkova, “Heart valve diseases in pregnancy,” in Heart Valve Disease: State of the Art, Springer International Publishing, 2019, pp. 257–269.
M. Cauldwell et al., “The management of labour in women with cardiac disease: need for more evidence?,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 124, no. 9. Blackwell Publishing Ltd, pp. 1307–1309, Aug. 01, 2017, doi: 10.1111/1471-0528.14547.
E. Ertekin et al., “Ventricular tachyarrhythmia during pregnancy in women with heart disease: Data from the ROPAC, a registry from the European Society of Cardiology,” Int. J. Cardiol., vol. 220, pp. 131–136, Oct. 2016, doi: 10.1016/j.ijcard.2016.06.061.
M. Christensen, C. S. Kronborg, N. Eldrup, N. B. Rossen, and U. B. Knudsen, “Preeclampsia and cardiovascular disease risk assessment – Do arterial stiffness and atherosclerosis uncover increased risk ten years after delivery?,” Pregnancy Hypertens. An Int. J. Women’s Cardiovasc. Heal., vol. 6, no. 2, pp. 110–114, Apr. 2016, doi: 10.1016/J.PREGHY.2016.04.001.
C. K. Silversides et al., “Pregnancy Outcomes in Women With Heart Disease: The CARPREG II Study,” J. Am. Coll. Cardiol., vol. 71, no. 21, pp. 2419–2430, May 2018, doi: 10.1016/J.JACC.2018.02.076.
N. Bhatla et al., “Cardiac disease in pregnancy,” Int. J. Gynecol. Obstet., vol. 82, no. 2, pp. 153–159, Aug. 2003, doi: 10.1016/S0020-7292(03)00159-0.
W. J. Franklin, R. Rokey, M. R. Foley, and M. A. Belfort, “Cardiac disease and pregnancy,” in Critical Care Obstetrics, 2018.
R. Rylander, “Pre-eclampsia during pregnancy and cardiovascular disease later in life: the case for a risk group,” Arch. Gynecol. Obstet., vol. 292, no. 3, pp. 519–521, 2015, doi: 10.1007/s00404-015-3676-3.
S. Satyan, R. P. Light, and R. Agarwal, “Relationships of N-Terminal Pro-B-Natriuretic Peptide and Cardiac Troponin T to Left Ventricular Mass and Function and Mortality in Asymptomatic Hemodialysis Patients,” Am. J. Kidney Dis., 2007, doi: 10.1053/j.ajkd.2007.08.017.
“Диагностика и лечение сердечно-сосудистых заболеваний при беременности,” 2013.
“(44)Бокерия_Л_А_,_Ревишвили_А_Ш_,_Неминущий.” .
K. Aasa, “Maternal Cardiovascular Adaptations in Rodent Models of Pregnancy Complications,” 2015.
A. Balaceanu, “B-type natriuretic peptides in pregnant women with normal heart or cardiac disorders,” Med. Hypotheses, vol. 121, pp. 149–151, Dec. 2018, doi: 10.1016/J.MEHY.2018.09.034.
M. Christensen, C. S. Kronborg, N. Eldrup, N. B. Rossen, and U. B. Knudsen, “Preeclampsia and cardiovascular disease risk assessment – Do arterial stiffness and atherosclerosis uncover increased risk ten years after delivery?,” Pregnancy Hypertens. An Int. J. Women’s Cardiovasc. Heal., vol. 6, no. 2, pp. 110–114, Apr. 2016, doi: 10.1016/J.PREGHY.2016.04.001.
V. Regitz-Zagrosek et al., “ESC Guidelines on the management of cardiovascular diseases during pregnancy,” Eur. Heart J., vol. 32, no. 24, pp. 3147–3197, Dec. 2011, doi: 10.1093/eurheartj/ehr218.
K. Adam, “Pregnancy in Women with Cardiovascular Diseases,” Methodist DeBakey cardiovascular journal, vol. 13, no. 4. 2017, doi: 10.14797/mdcj-13-4-209.
K. Tanaka et al., “Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease,” Circ. J., vol. 80, no. 10, 2016, doi: 10.1253/circj.CJ-15-0617.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 M.K. Uzokova, Sh. Togaymurodova
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
All Rights Reserved.
